Canine acute leukaemia: 50 cases (1989–2014)4. (12th July 2016)

• Record Type: Journal Article
• Authors: Bennett, A. L.; Williams, L. E.; Ferguson, M. W.; Hauck, M. L.; Suter, S. E.; Lanier, C. B.; Hess, P. R.
• Is Part Of: Veterinary and comparative oncology. Volume 15:Number 3(2017:Sep.)
• Page Start: 1101
• Page End: 1114
• Publication Date: 2016-07-12
• Subjects: acute leukaemia -- canine -- chemotherapy -- CHOP -- immunophenotype; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12251
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: Acute leukaemia (AL) is a bone marrow malignancy of hematopoietic progenitors that historically is poorly responsive to treatment. With the widespread adoption of dose‐intense chemotherapy, more human patients attain long‐term survivals, but whether comparable progress has been made in canine AL is unknown. To investigate this question, medical records from three academic veterinary hospitals were reviewed. Fifty dogs met the criteria for AL, having excess circulating or marrow blasts, a major cytopenia(s), and no substantial lymphadenopathy. Thirty‐six dogs received cytotoxic chemotherapy; 23 achieved a complete or partial response for a median of 56 days (range, 9–218). With failure or relapse, 14 dogs were rescued. Median survival with treatment was poor at 55 days (range, 1–300). Untreated ( n = 6) and palliatively‐treated ( n = 8) dogs lived a median of 7.5 days. Most dogs developed chemoresistance within weeks of initiating treatment, and consequently, survival times for AL remain disappointingly short.